SEC Form 4 · accession 0001470831-26-000626

BridgeBio Pharma, Inc. · BBIO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jun 22, 2026

Accepted (ET)

Jun 24, 2026 · 6:05 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001743881

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F2	Jun 22, 2026	A	3,990	$0.00	A	10,579	D
Common Stock^F3	holding	—	—		—	20,000	I	By The Dachille 2012-1 Family Trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F4	$68.92	Jun 22, 2026	A	5,277	A	—	Jun 21, 2036	Common Stock	5,277	5,277	D

F1Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
F2Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3These shares are owned directly by The Dachille 2012-1 Family Trust for the benefit of the Reporting Person's children, for which the Reporting Person's spouse is the trustee. The Reporting Person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose.
F4The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

Exhibit 24 - Power of Attorney